Journal
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
Volume 101, Issue -, Pages 122-128Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2019.03.020
Keywords
Alzheimer's disease; Dementia; Race; Randomized controlled trial; External validity; Precision medicine
Categories
Funding
- Italian Ministry of Health [GR-2016-02364975]
- Nestle
- Pfizer
- European Federation Pharmaceutical Industries and Associates
- Servier
- Sanofi
- Novartis
- GSK
- Lilly
- Innovative Medicines Initiative
Ask authors/readers for more resources
Introduction: Race is an important health determinant and should adequately be considered in research and drug development protocols targeting Alzheimer's disease (AD). Methods: A systematic review of available randomized controlled trials (RCTs) on the currently marketed treatments for AD was conducted with the aim of 1) documenting the reporting of race, and 2) exploring the impact of race on the efficacy and safety/tolerability of the considered medications. Results: Overall, 59.2% of the 49 retained RCTs reported information concerning the race of participants. Only a striking minority of enrolled patients was constituted of blacks and Hispanics. None on the retained studies reported results on the efficacy and safety/tolerability of the tested treatment separately for racial groups nor performed sensitivity analyses accounting for the race of participants. Discussion: Race has insufficiently been reported in previous interventional studies on AD. Its potential association with the effectiveness and safety/tolerability of the tested medications has completely been neglected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available